XML 41 R30.htm IDEA: XBRL DOCUMENT v3.21.2
Note 12 - Segment Information (Tables)
6 Months Ended
Sep. 30, 2021
Notes Tables  
Schedule of Segment Reporting Information, by Segment [Table Text Block]
  

Three Months Ended September 30,

  

Six Months Ended September 30,

 
  

2021

  

2020

  

2021

  

2020

 

Total revenues (a)

                

Sterilization and Disinfection Control

 $14,033  $11,552  $29,183  $24,619 

Biopharmaceutical Development

  10,555   9,131   19,432   15,080 

Instruments

  6,970   7,558   14,532   15,238 

Continuous Monitoring

  4,282   3,619   7,613   6,864 

Total revenues (a)

 $35,840  $31,860  $70,760  $61,801 
                 

Gross profit (loss)

                

Sterilization and Disinfection Control

 $10,486  $8,770  $21,914  $18,790 

Biopharmaceutical Development

  6,601   6,212   11,293   10,678 

Instruments

  4,112   4,852   8,772   9,541 

Continuous Monitoring

  2,016   1,368   3,468   2,552 

Reportable segment gross profit

  23,215   21,202   45,447   41,561 

Corporate and Other (b)

  (75)  83   (96)  64 

Gross profit

 $23,140  $21,285  $45,351  $41,625 

Reconciling Items:

                

Operating expenses

  18,939   16,815   38,027   33,585 

Operating income

  4,201   4,470   7,324   8,040 

Nonoperating (income) expense, net

  (342)  2,086   1,363   4,902 

Earnings before income taxes

 $4,543  $2,384  $5,961  $3,138 
Reconciliation of Assets from Segment to Consolidated [Table Text Block]
  

September 30,

  

March 31,

 
  

2021

  

2021

 

Sterilization and Disinfection Control

 $2,187  $2,333 

Biopharmaceutical Development

  3,706   4,162 

Instruments

  4,566   3,253 

Continuous Monitoring

  1,658   1,430 

Total inventories

 $12,117  $11,178